Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey09-15

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467042217?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/q5n3TDf7nbVINn50kvCsRg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7a22f3614201323e94dad1d5cc4885d1","is_english":true,"pubTime":"2024-09-15 05:39","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2467042217","market":"us","top_or_hot":-1,"title":"Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock","media":"Insider Monkey","content":"<div>\n<p>We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands ...</p>\n\n<a href=\"https://finance.yahoo.com/news/allogene-therapeutics-inc-allo-short-213959580.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-15 05:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/allogene-therapeutics-inc-allo-short-213959580.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands ...</p>\n\n<a href=\"https://finance.yahoo.com/news/allogene-therapeutics-inc-allo-short-213959580.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALLO","symbol_name":"Allogene Therapeutics Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-inc-allo-short-213959580.html","article_id":"2467042217","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/q5n3TDf7nbVINn50kvCsRg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7a22f3614201323e94dad1d5cc4885d1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467042217","pubTimestamp":1726349999,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers.In this article, we are going to take a look at where Allogene Therapeutics, Inc.  stands against the other cancer stocks.These factors are driving ongoing breakthroughs in the oncology market and enhancing its prospects. Back in 2023, over 25 new oncology active substances were introduced globally, along with the initiation of more than 2,000 new clinical trials. These trials span innovative treatments such as cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies. In 2023, the global oncology market was valued at around $201.75 billion and is projected to surpass $518.25 billion by 2032, with a compound annual growth ra","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALLO":"Allogene Therapeutics Inc.","SQQQ":"纳指三倍做空ETF","TQQQ":"纳指三倍做多ETF","CAGR":"California Grapes International, Inc.","BK4159":"经销商",".IXIC":"NASDAQ Composite","QID":"纳指两倍做空ETF","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"Allogene Therapeutics,Inc.(ALLO)：卖空情绪看跌这只癌症股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1,"CAGR":1,".IXIC":0.9,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands against the other cancer stocks.\nCancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences. As of 2024, 11 of the top 15 diseases globally by the number of active drugs were cancer-related. Breast cancer led the pack with approximately 1,031 active drugs in development. According to WHO, by 2050, over 35 million new cancer cases are projected, marking a 77% increase from the estimated 20 million cases in 2022. This sharp rise in the global cancer burden is driven by an aging and expanding population, along with increased exposure to various risk factors, many of which are linked to socioeconomic development. Additionally, low- and middle-income countries have access to less than half of the cancer medications deemed essential by the World Health Organization (WHO), while the cancer burden in these areas continues to grow. Without action, nearly 75% of global cancer deaths are projected to occur in these regions within the next decade.\nTraditionally, cancer drugs were designed to slow cell replication or kill cancer cells more quickly than healthy ones. While effective for certain cancer types, new methods are now emerging, such as modifying immune cells, utilizing mRNA, and enabling early detection through simple blood tests. Advancing the understanding, prevention, screening, and treatment of cancer is critical to reducing its global burden, but it comes at a rising cost, with global oncology spending projected to surpass $250 billion this year.\nWith this in mind, biotech and pharmaceutical companies are racing to develop cutting-edge therapies for cancers such as lung, breast, and prostate. As no single cure for cancer exists, developing a cancer drug that can treat multiple types of the disease is highly lucrative. For instance, Merck’s Keytruda generated $25 billion in revenue last year alone. Even in its fourth year on the market, back in 2018, the drug brought in $7.2 billion for the company. Moreover, In 2023, German biotechnology company BioNTech SE and the UK government signed a Memorandum of Understanding (MoU) to deliver personalized mRNA-based cancer immunotherapies to up to 10,000 patients by 2030.\nThese factors are driving ongoing breakthroughs in the oncology market and enhancing its prospects. Back in 2023, over 25 new oncology active substances were introduced globally, along with the initiation of more than 2,000 new clinical trials. These trials span innovative treatments such as cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies. In 2023, the global oncology market was valued at around $201.75 billion and is projected to surpass $518.25 billion by 2032, with a compound annual growth rate (CAGR) of 11.3% from 2024 to 2032 (as per estimates by Fortune Business Insights). This growth is driven by the increasing prevalence of cancer, the introduction of new drugs, product approvals, and expanding research in the field.\nOur Methodology\nTo compile our list of the 10 worst cancer stocks to buy according to short sellers, we focused on cancer-related stocks with substantial short interest (at least 10%). Despite this, these stocks remain favored by hedge funds and market analysts. The list is ranked based on the percentage of outstanding shares that have been sold short, in ascending order.\nWhy are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n A biotechnologist in a laboratory testing an Immuno-oncology treatment. \nAllogene Therapeutics, Inc. (NASDAQ:ALLO)\nShort % of Float: 28.65%\nNumber of Hedge Fund Holders: 23\nAllogene Therapeutics, Inc. (NASDAQ:ALLO) focuses on developing and commercializing allogeneic CAR-T (chimeric antigen receptor T) therapies for cancer, with a pipeline featuring several candidates for both hematological and solid tumors.\nOppenheimer initiated coverage of Allogene Therapeutics, Inc. (NASDAQ:ALLO) with an Outperform rating and a reduced price target of $11, down from $13. The firm’s analysis suggests that CAR-T therapies perform effectively in low-disease settings, based on translational data and recent experiences with CAR-Ts in autoimmunity. Oppenheimer anticipates that ALLO-329 will be ready for a new drug application filing in Q1 2025. Conversely, Citi has increased its price target for Allogene Therapeutics, Inc. (NASDAQ:ALLO) to $8 from $7, maintaining a Buy rating following the Q2 report. Citi’s update highlights the company’s steady progress in advancing its realigned pipeline.\nDespite facing attention from short sellers, hedge funds appear to be bullish on Allogene Therapeutics, Inc. (NASDAQ:ALLO). In Q2 2024, 23 hedge funds held positions in the biotechnology company, up from 18 in the previous quarter. The largest stakeholder was Michael Rockefeller and Karl Kroeker's Woodline Partners, with 4.35 million shares valued at $10.15 million.\nOverall ALLO ranks 1st on our list of the worst cancer stocks to buy according to short sellers. While we acknowledge the potential of ALLO as an investment, with the artificial intelligence revolution just beginning, there are lesser-known AI stocks trading at attractive valuations that could offer even greater promise for portfolio diversification. If you're seeking an AI stock with even more promise than ALLO and trading at less than 5 times its earnings, check out our report about the cheapest AI stock.   \nREAD NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.   \nDisclosure: None. This article is originally published at Insider Monkey.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467042217"}